Form 4: Imunon CEO Stacy Lindborg Reports Stock Option Grant

Imunon's CEO, Stacy Lindborg, reported the acquisition of stock options exercisable for 112,500 shares of common stock.

Summary

• On May 13, 2024, Stacy Lindborg, the President and CEO of Imunon, Inc., was granted stock options to purchase 112,500 shares of Imunon's common stock.
• The exercise price of these options is $1.48 per share, which was the closing price of Imunon's common stock on the grant date.
• The options vest in four equal installments, starting one year from the grant date and continuing annually for the subsequent three years.
• The options expire ten years from the grant date, on May 13, 2034.
• Following this transaction, Ms. Lindborg directly owns 126,666 shares of Imunon's common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed neutrally to positively as it aligns management with shareholder interests. The vesting schedule suggests a long-term commitment.

Positives

• The grant of stock options to the CEO aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• The vesting schedule of 1/4 per year over four years is a standard vesting arrangement.
• The ten-year expiration date is also a common practice for stock options.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to increase shareholder value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

Imunon, Stock Options, Form 4, Beneficial Ownership, Executive Compensation, IMNN, Stacy Lindborg